title: VESGEN 2D: automated, user-interactive software for quantification and mapping of angiogenic and lymphangiogenic trees and networks.
abstract: Quantification of microvascular remodeling as a meaningful discovery tool requires mapping and measurement of site-specific changes within vascular trees and networks. Vessel density and other critical vascular parameters are often modulated by molecular regulators as determined by local vascular architecture. For example, enlargement of vessel diameter by vascular endothelial growth factor (VEGF) is restricted to specific generations of vessel branching (Parsons-Wingerter et al., Microvascular Research72: 91, 2006). The averaging of vessel diameter over many successively smaller generations is therefore not particularly useful. The newly automated, user-interactive software VESsel GENeration Analysis (VESGEN) quantifies major vessel parameters within two-dimensional (2D) vascular trees, networks, and tree-network composites. This report reviews application of VESGEN 2D to angiogenic and lymphangiogenic tissues that includes the human and murine retina, embryonic coronary vessels, and avian chorioallantoic membrane. Software output includes colorized image maps with quantification of local vessel diameter, fractal dimension, tortuosity, and avascular spacing. The density of parameters such as vessel area, length, number, and branch point are quantified according to site-specific generational branching within vascular trees. The sole user input requirement is a binary (black/white) vascular image. Future applications of VESGEN will include analysis of 3D vascular architecture and bioinformatic dimensions such as blood flow and receptor localization. Branching analysis by VESGEN has demonstrated that numerous regulators including VEGF(165), basic fibroblast growth factor, transforming growth factor beta-1, angiostatin and the clinical steroid triamcinolone acetonide induce 'fingerprint' or 'signature' changes in vascular patterning that provide unique readouts of dominant molecular signaling.
authors.affiliation: NASA Glenn Research Center, 21000 Brookpark Road, Cleveland, OH 44135, USA.
authors.forename: Mary B
authors.initials: MB
authors.lastname: Vickerman
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Keith
authors.forename: Terri L
authors.initials: TL
authors.lastname: McKay
authors.forename: Dan J
authors.initials: DJ
authors.lastname: Gedeon
authors.forename: Michiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Monica
authors.initials: M
authors.lastname: Montano
authors.forename: Ganga
authors.initials: G
authors.lastname: Karunamuni
authors.forename: Peter K
authors.initials: PK
authors.lastname: Kaiser
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Sears
authors.forename: Quteba
authors.initials: Q
authors.lastname: Ebrahem
authors.forename: Daniela
authors.initials: D
authors.lastname: Ribita
authors.forename: Alan G
authors.initials: AG
authors.lastname: Hylton
authors.forename: Patricia
authors.initials: P
authors.lastname: Parsons-Wingerter
mesh_terms: D000818:Animals; D003331:Coronary Vessels / Q000502:physiology; D006801:Humans; D042583:Lymphangiogenesis / Q000502:physiology*; D051379:Mice; D018919:Neovascularization, Physiologic / Q000502:physiology*; D011784:Quail; D012160:Retina / Q000187:drug effects; D012171:Retinal Vessels / Q000502:physiology; D012984:Software; D014222:Triamcinolone Acetonide / Q000494:pharmacology; D014584:User-Computer Interface
chemical_list: D014222:Triamcinolone Acetonide